The hiccup reflex arc involves the phrenic nerve (C3–C5 — diaphragm), vagus nerve (gastric, oesophageal, thoracic branches), and a putative "hiccup centre" in the upper cervical spinal cord and brainstem (nucleus tractus solitarius, reticular formation). Any structure along this arc — from the gastric fundus to the brainstem — can trigger hiccups. The clinical importance is that persistent hiccups (>48 hours) have identifiable organic causes in the majority of adult cases. A population-based study found that 80% of patients presenting to hospital with hiccups lasting >48 hours had a demonstrable underlying cause, most commonly gastrointestinal (GORD, gastric distension, oesophageal pathology), CNS, metabolic (uraemia, hyponatraemia, hypocalcaemia), or drug-related. The definition of hiccup duration is clinically important: acute hiccups last <48 hours (benign, self-limiting, usually gastrointestinal trigger), persistent hiccups last 48 hours to 1 month (investigate), intractable hiccups last >1 month (almost always have a serious underlying cause — CNS, malignancy, metabolic, or refractory GORD). Dexamethasone as a cause of hiccups is important to recognise in oncology patients — it is thought to act via direct stimulation of the hiccup centre and is dose-dependent. Reducing or switching the dexamethasone formulation or dosing timing (morning dosing only) can reduce hiccups without compromising the therapeutic effect.

GORD (gastro-oesophageal reflux disease) is the most commonly identifiable cause of persistent hiccups in primary care — the mechanism is oesophageal irritation stimulating the vagal branches that form part of the hiccup reflex arc. A therapeutic trial of a PPI (omeprazole 20 mg OD) is both diagnostic and therapeutic — resolution of hiccups with PPI treatment strongly implicates GORD as the cause. This is the most important first-line intervention in persistent hiccups without red flag features. Alcohol is a common and underappreciated cause of persistent hiccups — both through acute gastric distension/irritation and through its CNS depressant effects on the hiccup inhibitory pathways. A careful alcohol history should be taken in all patients with persistent hiccups. Post-operative hiccups are a recognised complication of abdominal and thoracic surgery, and of general anaesthesia (thought to be due to direct diaphragmatic irritation, gastric distension from air swallowing, and anaesthetic agent effects). They can significantly impair wound healing, nutrition, and sleep in post-operative patients and require active management.

The "diurnal pattern" of hiccups is one of the most useful clinical discriminators between functional/psychogenic and organic hiccups. Organic hiccups are present during sleep (they can wake the patient or occur continuously), whereas functional/psychogenic hiccups are characteristically absent during sleep — the hiccup reflex is suppressed by deep sleep stages, and the anxiety/hyperventilation-driven mechanisms that sustain psychogenic hiccups are not active during sleep. Asking "Do your hiccups wake you up at night, or are they present when you first wake up?" is a high-yield question. The Arnold's nerve (auricular branch of the vagus) ear reflex is a genuine and often overlooked cause of persistent hiccups — the auricular branch of CN X innervates the posterior external auditory canal, and stimulation (by wax, a hair, a foreign body) causes reflex vagal activation. Case reports document abolition of months-long hiccups by simple ear syringing. This should be examined in every patient with unexplained persistent hiccups — it is a 30-second examination that costs nothing and can be immediately therapeutic.

The chest X-ray is the single most valuable investigation in unexplained persistent hiccups — it can identify lung cancer (the most common cause of intractable hiccups from phrenic nerve invasion), mediastinal lymphadenopathy (lymphoma), pleural effusion (malignant or inflammatory), pericardial effusion, an elevated hemidiaphragm (phrenic nerve palsy from any cause — tumour, trauma, aortic aneurysm), and cardiomegaly (heart failure causing hiccups through vagal stimulation). It should be performed in all persistent hiccups before initiating drug treatment. Corrected calcium should be checked in all persistent hiccups — hypocalcaemia directly lowers the threshold for the hiccup reflex arc and is a well-documented reversible cause of persistent hiccups. Uraemia causes hiccups through direct irritation of the diaphragm by retained uraemic toxins — this is a relatively specific symptom of advanced uraemia (along with uraemic frost, pericarditis, and encephalopathy) and may indicate a patient with known CKD has deteriorated. Prompt checking of U&E in a CKD patient with new persistent hiccups is always warranted.

The 2WW oesophageal cancer pathway is triggered by persistent hiccups combined with dysphagia because oesophageal cancer is the most lethal upper GI cancer (5-year survival only 15% overall — partly due to late diagnosis), and hiccups are a recognised early symptom of oesophageal cancer through vagal and phrenic nerve irritation by the tumour. NICE NG12 specifies that any patient aged ≥55 with unexplained dysphagia, or aged ≥55 with dysphagia plus at least one of: weight loss, reflux, nausea/vomiting, or upper abdominal pain = 2WW upper GI endoscopy. Persistent hiccups in this context lower the threshold further. Intractable hiccups in palliative patients require specific management — they cause profound deterioration in quality of life through sleep deprivation, poor nutrition (inability to eat comfortably), pain (intercostal muscle fatigue), social isolation, and psychological distress. The choice of palliative agent depends on the mechanism: metoclopramide (dopamine antagonist — reduces gastric distension/GORD component), haloperidol (central dopamine blockade — reduces CNS-mediated hiccups, commonly used in end-of-life care), baclofen (GABA-B agonist — reduces brainstem hiccup centre activity), or midazolam CSCI (continuous subcutaneous infusion — for terminal phase). A palliative care specialist should be involved in managing intractable hiccups in any seriously ill patient.

Baclofen has the best evidence among the drugs used for persistent hiccups — a 2015 Cochrane review identified it as the most supported pharmacological treatment based on the available (though limited) RCT and case series data. Its mechanism is suppression of the hiccup reflex arc at the level of the medullary reticular formation via GABA-B receptor agonism. The key clinical consideration is renal dosing — baclofen is almost entirely renally excreted and accumulates in renal impairment, causing profound CNS toxicity (drowsiness, confusion, respiratory depression, coma). In a patient with CKD where uraemia may itself be causing the hiccups, baclofen must be used at the lowest possible dose (2.5 mg OD–BD) with careful monitoring. Chlorpromazine is the only BNF-licensed drug specifically for hiccups in the UK, which is historically significant — it was discovered during the 1950s phenothiazine drug development era and recognised as effective for hiccups before its antipsychotic use became dominant. However its extensive side effect profile (orthostatic hypotension, sedation, extrapyramidal effects, QT prolongation, neuroleptic malignant syndrome) means it is now reserved for severe or refractory cases where other agents have failed. Haloperidol is preferred in palliative care because it can be given subcutaneously and has a more acceptable side effect profile at the low doses used for hiccups.

Opioid rotation for drug-induced hiccups is an important palliative care principle — different opioids have different side effect profiles due to differences in their receptor binding profiles and metabolite activity. A patient on morphine with intractable hiccups may have resolution with a switch to oxycodone or hydromorphone. This is far preferable to adding more drugs, which risks polypharmacy and drug interactions. The dexamethasone timing strategy (morning-only dosing) is based on the understanding that dexamethasone's CNS stimulant and appetite-stimulating effects are most pronounced in the first few hours after dosing — taking it in the morning aligns the peak effect with waking hours and avoids stimulation of the hiccup centre during the evening and night, when hiccups are often most distressing. In palliative patients on dexamethasone for malignant hiccups, this simple timing change can be tried before adding any additional drug. Gabapentin (100–300 mg TDS) has emerged as a useful second-line drug for hiccups with a neuropathic or CNS aetiology — case series in patients with brainstem lesions (MS, stroke, tumour) have shown significant response rates. It is particularly useful where baclofen is contraindicated (renal impairment) as gabapentin can also be dose-adjusted for renal function in a more predictable way.

The physiological basis for the many hiccup "folk remedies" is now reasonably well understood — the majority work through one of two mechanisms: (1) CO₂ elevation (breath-holding, paper bag rebreathing) — raised PCO₂ suppresses the phrenic nerve excitability and the respiratory drive component of the hiccup reflex; (2) Vagal stimulation (cold water, swallowing, Valsalva, carotid sinus massage) — activating vagal afferents inhibits the hiccup reflex arc at brainstem level, similar to how a high vagal tone protects against hiccup perpetuation. The HiccAway straw (a straw with an added resistance valve that requires significant subatmospheric pressure to drink through) was marketed as a device that simultaneously performs a Valsalva manoeuvre and engages the swallowing/sucking reflex, and a small RCT (JAMA Network Open 2021) showed a 92% success rate for acute hiccups compared to traditional methods. While not NHS-available, it represents the evidence base for the combined approach. For persistent functional/psychogenic hiccups, diaphragmatic breathing retraining is the most evidence-based non-pharmacological intervention — it directly targets the respiratory dysrhythmia component and has shown benefit in small case series. A physiotherapist or respiratory physiotherapist with expertise in breathing retraining can provide this formally.

The 48-hour return rule is the most important safety-netting instruction for hiccups — it converts what appears to be a trivial presenting complaint into an appropriately managed clinical problem with a defined escalation trigger. Many serious diagnoses (oesophageal cancer, posterior fossa tumour, pulmonary embolism, uraemia) first present to primary care as "persistent hiccups" and are not diagnosed promptly because the symptom is dismissed. Documenting "hiccups — return if persisting beyond 48 hours or if any of: dysphagia, weight loss, neurological symptoms, chest pain" in the clinical records both protects the patient and provides appropriate medicolegal documentation. Baclofen discontinuation safety is important — patients are sometimes stopped abruptly when hiccups resolve, which can precipitate withdrawal seizures (baclofen shares this risk with alcohol and benzodiazepines — all act at GABA receptors). The instruction to taper baclofen over 1–2 weeks must be given to every patient prescribed it. A dose reduction schedule (reduce by 5 mg every 3–4 days) should be written in the consultation note and explained to the patient.